Dr. Motzer on the Efficacy of Cabozantinib in RCC

EP: 1.NEJM Data Underscore Frontline Nivolumab/Cabozantinib Benefit Over Sunitinib in Advanced RCC

Now Viewing

EP: 2.Dr. Motzer on the Efficacy of Cabozantinib in RCC

EP: 3.Dr. Choueiri on the CheckMate-9ER Exploratory Analysis in Advanced RCC

EP: 4.CheckMate-9ER Sets the Bar for Research With Triplets, Response-Guided Therapy in mRCC

EP: 5.Choueiri and Motzer Chat on CheckMate-9ER and Other RCC Research

Robert J. Motzer, MD, Kidney Cancer section head, genitourinary oncology service and Jack and Dorothy Byrne chair in Clinical Oncology with Memorial Sloan Kettering Cancer Center, discusses the efficacy of cabozantinib (Cabometyx) in patients with renal cell carcinoma (RCC).

While cabozantinib was added to the RCC treatment arsenal, it had demonstrated exceptional activity in patients, Motzer says. The phase 3 METEOR trial (NCT01865747) exemplified the beneficial activity with the agent, as investigators observed an overall survival (OS) benefit with its use over that of everolimus (Afinitor). This is particularly important, as OS benefit has been elusive in nearly all other prior RCC clinical trials, Motzer notes.

Currently, the agent is widely used in the second- and third-line settings, Motzer explains. As such, it was expected that the combination of cabozantinib plus nivolumab (Opdivo) in the phase 3 CheckMate-9ER trial (NCT03141177) would demonstrate notable efficacy, Motzer concludes.